Pharmaceuticals - Thailand

Thailand

The revenue in the Pharmaceuticals market in Thailand is expected to reach US$1,977.00m in 2024.
The largest market in Thailand is Oncology Drugs, projected to have a market volume of US$360.00m in 2024.
The revenue in Thailand's Pharmaceuticals market is expected to grow at an annual growth rate of 5.88% (CAGR 2024-2028), resulting in a market volume of US$2,485.00m by 2028.
In comparison to other countries, United States is projected to generate the highest revenue of US$636.90bn in 2024.
Thailand's pharmaceutical market is experiencing a surge in demand for herbal medicines and traditional remedies.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

Thailand has been experiencing significant growth in its pharmaceuticals market in recent years.

Customer preferences: Thai consumers have been increasingly demanding high-quality healthcare services, including pharmaceutical products. They prefer products that are affordable, effective, and have minimal side effects. Moreover, the aging population in Thailand has led to a rise in chronic diseases, which has further increased the demand for pharmaceutical products.

Trends in the market: One of the major trends in the Thai pharmaceuticals market is the shift towards generic drugs. This is due to the government's policy to promote the use of affordable generic drugs and reduce healthcare costs. Another trend is the increasing investment in research and development by pharmaceutical companies to develop innovative drugs and treatments. Additionally, there has been a rise in the use of digital technologies in healthcare, such as telemedicine and e-pharmacies, which has made healthcare services more accessible and convenient for consumers.

Local special circumstances: The Thai government has implemented several policies to promote the growth of the pharmaceuticals market, such as the establishment of the Thailand Center of Excellence for Life Sciences (TCELS) to support research and development in the industry. Moreover, the government has introduced tax incentives to attract foreign pharmaceutical companies to invest in the country.

Underlying macroeconomic factors: Thailand's strong economic growth and increasing healthcare expenditure have contributed to the growth of the pharmaceuticals market. Additionally, the country's strategic location and well-developed infrastructure have made it an attractive destination for pharmaceutical companies to invest in.In conclusion, Thailand's pharmaceuticals market is experiencing significant growth due to the increasing demand for high-quality healthcare services, the shift towards generic drugs, and the government's policies to promote the industry. The use of digital technologies and the country's favorable macroeconomic conditions are also contributing to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.